KalVista Pharmaceuticals (KALV) Presents Data on HAE Attacks in Patients Receiving Long-Term Prophylaxis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2024
- Wall St edges lower as Powell signals caution; Tesla jumps after delivery data
- Tesla (TSLA) stock jumps after Tesla Q2 deliveries beat consensus
- Fed's Powell says more evidence of falling inflation needed before rate cut
- Goldman: Hedge funds sold global equities at the fastest pace in two years in June
- BofA: Don't sell in May and don't go away
- Rapid7 (RPD) to Acquire Cyber Asset Attack Surface Management Company, Noetic Cyber
- Cassava Sciences (SAVA) Provides Update on Government Investigations
- Tesla (TSLA) produces about 411,000 vehicles and delivers 444,000 vehicles in second quarter
- Cedar Fair L.P. (FUN), Six Flags (SIX) Announce Merger of Equals is Successfully Completed
- Spirit Airlines (SAVE) reports appointment of Fred Cromer as EVP and CFO
- Midday movers: Spirit Aerosystems, Tesla rise; Chewy falls
- Midday movers: Nike and Accolade fall; Humana and Infinera rise
- After-hours movers: Nike, Infinera, Accolade and more
- Midday movers: Micron, Levi Strauss, Walgreens and International Paper fall
- After-hours movers: Micron Technology, Levi, AeroVironment, and more
KalVista Pharmaceuticals Presents Data on HAE Attacks in Patients Receiving Long-Term Prophylaxis at the Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2023 International Conferen
October 24, 2023 6:30 AM EDTCAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the presentation of a novel analysis characterizing hereditary angioedema (HAE) attacks occurring in... More
